摘要
Weng and coauthors enrolled 5,535 type 2 diabetic patients in a study of the combined effect of metformin with sitagliptin,nearly half achieving HbAlc〈7.0%,with an average 0.85%fall from a baseline of 8.03%.This supports many previous studies of the effect of such combined metformin plus DPP-4 inhibitor regimens.
Weng and coauthors enrolled 5,535 type 2 diabetic patients in a study of the combined effect of metformin with sitagliptin,nearly half achieving HbAlc<7.0%,with an average 0.85%fall from a baseline of 8.03%.This supports many previous studies of the effect of such combined metformin plus DPP-4 inhibitor regimens.After 16 weeks the authors then randomized 2,202 of those not achieving HbAlc<7%to either of the sulfonylureas glimepiride(mean dose 1.8 mg)
